Abstract
The molecular mechanisms for the interferon beta (IFNbeta) treatment of multiple sclerosis (MS) remain to be characterized. Using cDNA microarray technology, we have compared the gene expression profile of T and non-T cells derived from relapsing-remitting MS before and after treatment with IFNbeta-1b. IFNbeta treatment significantly altered expression of 21 genes out of 1263 at 3 and 6 months after treatment. These genes included nine with IFN-responsive promoter elements. Whereas there was no change in Th1 or Th2 marker genes, some of the changes were unexpected but coincided with the beneficial effect of IFNbeta in MS.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antigens, Surface / drug effects
-
Antigens, Surface / genetics
-
Antigens, Surface / immunology
-
Biomarkers / blood
-
Cytokines / drug effects
-
Cytokines / genetics
-
Cytokines / immunology
-
Female
-
Gene Expression Regulation / drug effects*
-
Gene Expression Regulation / immunology
-
Genes / drug effects*
-
Genes / immunology
-
Humans
-
Interferon-beta / pharmacology*
-
Interferon-beta / therapeutic use
-
Male
-
Middle Aged
-
Multiple Sclerosis / blood
-
Multiple Sclerosis / drug therapy*
-
Multiple Sclerosis / genetics*
-
Oligonucleotide Array Sequence Analysis
-
T-Lymphocytes / drug effects*
-
T-Lymphocytes / immunology
-
Th1 Cells / drug effects
-
Th1 Cells / immunology
-
Th2 Cells / drug effects
-
Th2 Cells / immunology
-
Treatment Outcome
Substances
-
Antigens, Surface
-
Biomarkers
-
Cytokines
-
Interferon-beta